KAS
ARQT icon

Kemnay Advisory Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Kemnay Advisory Services’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27K Buy
1,029
+108
+12% +$2.52K ﹤0.01% 559
2026
Q1 		$21.7K Buy
921
+699
+315% +$17.8K ﹤0.01% 644
2025
Q4 		$6.45K Buy
+222
New +$5.68K ﹤0.01% 821

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Kemnay Advisory Services's ARQT Position: Q2 2026 in Review

Kemnay Advisory Services increased its Arcutis Biotherapeutics (ARQT) stake by 12% in Q2 2026, buying an estimated $2.52K and bringing the position to 1,029 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #559.

Kemnay Advisory Services first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Kemnay Advisory Services held 1,029 shares of Arcutis Biotherapeutics worth $27K as of Q2 2026.
  • Kemnay Advisory Services bought 108 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.52K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #559 holding.
  • Kemnay Advisory Services first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.